Tracheobronchomalacia and a lower respiratory tract infection
Conditions
Interventions
Inhaled 2,5 mg DNase or placebo, twice daily for two weeks.
Sponsors
Erasmus MC-Sophia Children's Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1. Children aged 2-18 years with tracheobronchomalacia (diagnosed bronchoscopically); 2. Symptoms of a lower respiratory tract infection.
Exclusion criteria
Exclusion criteria: 1. Indication for a course of antibiotics at presentation (assessed by pediatric pulmonologist); 2. Co-existing chronic pulmonary disease (e.g. cystic fibrosis, broncho pulmonary dysplasia or primary ciliary dyskinesia); 3. History of oesophageal atresia; 4. Neuromuscular disease or psychomotor retardation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in mean daily Cough Symptom Score (CSS). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Need for additional antibiotics; 2. Mean daily “cough severity” and “coughability of sputum” (VAS-score); 3. CSS and VAS on each treatment day; 4. Lung function (FEV1, FVC, PEF, MEF25, RINT); 5. Parent’s perception about treatment efficacy; 6. Doctor’s diagnosed end of infection after 1 and 2 weeks treatment. | — |
Contacts
Public ContactR. Boogaard
Erasmus Medical Center, Sophia Children’s Hospital, Department of Pediatric Pulmonology, SB-2666, P.O. Box 2060
Outcome results
None listed